{
    "nctId": "NCT02393833",
    "briefTitle": "IBCSG Trial 22-00 Serum Substudy",
    "officialTitle": "Assessment of Vascular Endothelial Growth Factor (VEGF), Soluble Her2 Protein (NRP, Neu-Related Protein), and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in Serum Samples of Patients Participating in Trial IBCSG 22-00",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 136,
    "primaryOutcomeMeasure": "Change from baseline to 18 months in serum VEGF values",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must be randomized to the core protocol. Written informed consent for the serum substudy must be signed and dated by the patient and investigator\n* Patient must not have begun CM maintenance (if randomized to CM maintenance)\n\nExclusion Criteria:\n\n* Patient not randomized to the core protocol\n* Patient already begun CM maintenance (if randomized to CM maintenance)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}